EMA recommends conditional approval for Pfizer/BioNTech's COVID-19 vaccine

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting Pfizer/BioNTech’s COVID-19 vaccine a conditional marketing authorisation (CMA) in the EU. Earlier this month, the EMA announced that it had scheduled an ‘exceptional meeting’ of the CHMP on 21 December to review additional data for the Pfizer/BioNTech vaccine. Originally, a meeting had been planned for 29 December, but was brought forward as the vaccine gained emergency approvals in the US, UK and other countries.